LQT Therapeutics Announces the Appointment of Dr. Robert Booth to its Board of Directors

Alyssia Watkin Portfolio News, Thryv Therapeutics

Company Strategically Strengthens its Fight Against Long QT Syndrome with Novel Kinase Drug Development Expertise

Today, LQT Therapeutics, Inc. (LQTT) announced the addition of Dr. Robert Booth to its Board of Directors. Dr. Booth brings more than 30 years of biopharmaceutical industry experience to the company, most recently as founder and chief executive officer of Virobay Inc. In addition, he has served as operating partner and senior advisor at TPG Biotech.

“A major objective for us at LQTT after our recent Series A financing, has been to enrich our board of directors with experienced, respected and highly accomplished drug development executives as we continue to advance our clinical programs,” said Paul F. Truex, Chairman and Chief Executive Officer of LQT Therapeutics.“Robert has extensive strategic and operational experience in early-stage drug development and specifically with the development of commercially successful kinase inhibitors. Robert is a veteran of the industry, and a superb scientist with wide-ranging expertise in many aspects of drug development and a particular focus in supporting the advancement of novel therapies for important diseases for which the existing treatment options are suboptimal.”

Prior to Virobay, Dr. Booth was the chief scientific officer at Celera Genomics, where he was responsible for all discovery and development activities. He conceived and initiated the BTK inhibitor program that was ultimately licensed to Pharmacyclics, and from which Imbruvica was developed and approved. Imbruvica is a novel kinase inhibitor used for the treatment of many B cell non-Hodgkin’s lymphomas (NHL). Dr. Booth served on the board of directors of Pharmacyclics until its acquisition by AbbVie. Prior to Celera, he was senior vice president for Roche in Palo Alto, California. He was a member of the global research management team and the business development committee, which oversaw licensing opportunities. Dr. Booth received his BSc and PhD in biochemistry from the University of London.

About LQT Therapeutics, Inc.

LQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and other arrhythmias based on research developed at Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. Launched in 2019 by the Fonds de Solidarité FTQ. LQT Therapeutics, Inc. was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development. For more information, please visit www.lqttrx.com

For more information:

Daphne Doucet | daphne@lqttrx.com | 514-973-0915